Cargando…

Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer

Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Meijun, Giridhar, Karthik V., Tian, Yijun, Tschannen, Michael R., Zhu, Jing, Huang, Chiang-Ching, Kilari, Deepak, Kohli, Manish, Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609954/
https://www.ncbi.nlm.nih.gov/pubmed/28969022
http://dx.doi.org/10.18632/oncotarget.19476
_version_ 1783265697144504320
author Du, Meijun
Giridhar, Karthik V.
Tian, Yijun
Tschannen, Michael R.
Zhu, Jing
Huang, Chiang-Ching
Kilari, Deepak
Kohli, Manish
Wang, Liang
author_facet Du, Meijun
Giridhar, Karthik V.
Tian, Yijun
Tschannen, Michael R.
Zhu, Jing
Huang, Chiang-Ching
Kilari, Deepak
Kohli, Manish
Wang, Liang
author_sort Du, Meijun
collection PubMed
description Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC.
format Online
Article
Text
id pubmed-5609954
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56099542017-09-29 Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer Du, Meijun Giridhar, Karthik V. Tian, Yijun Tschannen, Michael R. Zhu, Jing Huang, Chiang-Ching Kilari, Deepak Kohli, Manish Wang, Liang Oncotarget Research Paper Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC. Impact Journals LLC 2017-07-22 /pmc/articles/PMC5609954/ /pubmed/28969022 http://dx.doi.org/10.18632/oncotarget.19476 Text en Copyright: © 2017 Du et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Du, Meijun
Giridhar, Karthik V.
Tian, Yijun
Tschannen, Michael R.
Zhu, Jing
Huang, Chiang-Ching
Kilari, Deepak
Kohli, Manish
Wang, Liang
Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title_full Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title_fullStr Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title_full_unstemmed Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title_short Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
title_sort plasma exosomal mirnas-based prognosis in metastatic kidney cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609954/
https://www.ncbi.nlm.nih.gov/pubmed/28969022
http://dx.doi.org/10.18632/oncotarget.19476
work_keys_str_mv AT dumeijun plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT giridharkarthikv plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT tianyijun plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT tschannenmichaelr plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT zhujing plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT huangchiangching plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT kilarideepak plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT kohlimanish plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer
AT wangliang plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer